The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF Study
Open accessAbstract
Aims: Inflammation is a central process in the pathophysiology of heart failure (HF), but trials targeting tumour necrosis factor (TNF)-α were largely unsuccessful. Interleukin (IL)-6 is an important inflammatory mediator and might constitute a potential pharmacologic target in HF. However, little is known regarding the association between IL-6 and clinical characteristics, outcomes and other inflammatory biomarkers in HF. We thus aimed to identify and characterize these associations. Methods and results: Interleukin-6 was measured in 2329 patients [89.4% with a left ventricular ejection fraction (LVEF) ≤ 40%] of the BIOSTAT-CHF cohort. The primary outcome was all-cause mortality and HF hospitalization during 2 years, with all-cause, cardiovascular (CV), and non-CV death as secondary outcomes. Approximately half (56%) of all included patients had plasma IL-6 values greater than the previously determined 95th percentile of normal values at baseline. Elevated N-terminal pro-brain natriuretic peptide, procalcitonin and hepcidin, younger age, TNF-α/IL-1-related biomarkers, or having iron deficiency, atrial fibrillation and LVEF > 40% independently predicted elevated IL-6 levels. IL-6 independently predicted the primary outcome [HR (95% confidence interval) per doubling: 1.16 (1.11–1.21), P < 0.001], all-cause mortality [1.22 (1.16–1.29), P < 0.001] and CV as well as non-CV mortality [1.16 (1.09–1.24), P < 0.001; 1.31 (1.18–1.45), P < 0.001], but did not improve discrimination in previously published risk models. Conclusions: In a large, heterogeneous cohort of HF patients, elevated IL-6 levels were found in more than 50% of patients and were associated with iron deficiency, reduced LVEF, atrial fibrillation and poorer clinical outcomes. These findings warrant further investigation of IL-6 as a potential therapeutic target in specific HF subpopulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Self-citationInflammation and the pathogenesis of atrial fibrillation
Hu, Y.-F., Chen, Y.-J., Lin, Y.-J., & Chen, S.-A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.2 · Cited by 1,089
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 1×
“3 The results of CANTOS and the accumulating evidence for the role of inflammation in HF resulted in renewed interest to investigate anti-inflammatory agents in HF. Interleukin-6 is a cytokine with both pro-inflammatory and anti-inflammatory properties.”
Background(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway
Maggio, M., Guralnik, J. M., Longo, D. L., & Ferrucci, L. (2006) · The Journals of Gerontology: Series A · doi:10.1093/gerona/61.6.575 · Cited by 692
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Becker, K. L., Nylén, E. S., White, J. C., Müller, B., & Snider, R. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021444 · Cited by 578
Inflammation – Cause or Consequence of Heart Failure or Both?
Van Linthout, S., & Tschöpe, C. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0337-9 · Cited by 465
Maeda, K., Tsutamoto, T., Wada, A., Mabuchi, N., Hayashi, M., Tsutsui, T., Ohnishi, M., Sawaki, M., Fujii, M., Matsumoto, T., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00912-8 · Cited by 418
Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
Jankowska, E. A., von Haehling, S., Anker, S. D., Macdougall, I. C., & Ponikowski, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs224 · Cited by 399
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro
Nijsten, M. W. N., Olinga, P., The, H. T., de Vries, E. G. E., Koops, H. S., Groothuis, G. M. M., Limburg, P. C., ten Duis, H. J., Moshage, H., Hoekstra, H. J., et al. (2000) · Critical Care Medicine · doi:10.1097/00003246-200002000-00028 · Cited by 295
Role of Inflammation in Heart Failure
Shirazi, L. F., Bissett, J., Romeo, F., & Mehta, J. L. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0660-3 · Cited by 278
Voors, A. A., Ouwerkerk, W., Zannad, F., van Veldhuisen, D. J., Samani, N. J., Ponikowski, P., Ng, L. L., Metra, M., ter Maaten, J. M., Lang, C. C., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.785 · Cited by 256
Self-citationMarcus, G. M., Whooley, M. A., Glidden, D. V., Pawlikowska, L., Zaroff, J. G., & Olgin, J. E. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.09.006 · Cited by 228
Wu, C., Lee, J.-K., Chiang, F., Yang, C.-H., Huang, S.-W., Hwang, J., Lin, J.-L., Tseng, C.-D., Chen, J.-J., & Tsai, C. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e31820a91b9 · Cited by 125
GDF 15 - A Novel Biomarker in the Offing for Heart Failure
George, M., Jena, A., Srivatsan, V., Rajaram, M., & Dhandapani, V. E. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160111125304 · Cited by 109
Ticinesi, A., Meschi, T., Lauretani, F., Felis, G. E., Franchi, F., Pedrolli, C., Barichella, M., Benati, G., Nuzzo, S. D., Ceda, G. P., et al. (2016) · Nutrients · doi:10.3390/nu8040186 · Cited by 106
Activation of the Cardiac Interleukin-6 System in Advanced Heart Failure
Plenz, G., Fang, S. Z., Tjan, T. D. T., Carsten, K., Baba Hideo, A., Erren, M., Flesch, M., Thomas, W., Scheld, H. H., & Deng Mario, C. (2001) · European Journal of Heart Failure · doi:10.1016/s1388-9842(01)00137-4 · Cited by 89
Todd, J. A., Simpson, P. A., Estis, J., Torres, V., & Wub, A. H. B. (2013) · Cytokine · doi:10.1016/j.cyto.2013.09.018 · Cited by 83
Gwechenberger, M., Hülsmann, M., Berger, R., Graf, S., Springer, C., Stanek, B., & Pacher, R. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2003.07.023 · Cited by 51
Eskandari, V., Amirzargar, A., Mahmoudi, M., Rahnemoon, Z., Rahmani, F., sadati, S. S. S., Rahmati, Z., Gorzin, F., Hedayat, M., & Rezaei, N. (2017) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-017-1680-2 · Cited by 42
Inflammation and Cardio-Renal Interactions in Heart Failure: A Potential Role for Interleukin-6
Hanberg, J. S., Rao, V. S., Ahmad, T., Chunara, Z., Mahoney, D., Jackson, K., Jacoby, D. L., Chen, M. X., Wilson, F. P., Tang, W. H. W., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.963 · Cited by 35
Self-citationBielecka-Dabrowa, A. M., Sakowicz, A., Pietrucha, T., Misztal, M., Chruściel, P., Rysz, J., & Banach, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-09564-9 · Cited by 22
TNFα antagonist upregulates interleukin-6 in rats with hypertensive heart failure
Haugen, E., Täng, M. S., Isic, A., Andersson, B., & Fu, M. L. X. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.08.047 · Cited by 15
Cited by
Murphy, S. P., Kakkar, R., McCarthy, C. P., & Januzzi, J. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.014 · Cited by 738
Self-citationHeart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 691
Inciardi, R. M., Adamo, M., Lupi, L., Cani, D. S., Di Pasquale, M., Tomasoni, D., Italia, L., Zaccone, G., Tedino, C., Fabbricatore, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa388 · Cited by 531
Self-citationAging Biomarker Consortium, Bao, H., Cao, J., Chen, M., Chen, M., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 376
Metadata
- Authors
- Markousis-Mavrogenis, G., Tromp, J., Ouwerkerk, W., Devalaraja, M., Anker, S. D., Cleland, J. G., Dickstein, K., Filippatos, G. S., van der Harst, P., Lang, C. C., Metra, M., Ng, L. L., Ponikowski, P., Samani, N. J., Zannad, F., Zwinderman, A. H., Hillege, H. L., van Veldhuisen, D. J., Kakkar, R., Voors, A. A., & van der Meer, P.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-14
- Volume
- 21
- Issue
- 8
- Pages
- 965-973
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2944333322
- Cited by
- 294
- References
- 27
- FWCI
- 18.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.